Lactobacillus acidophilus
Lactobacillus acidophilus is one of the most studied lactic acid bacteria, with research dating back decades documenting its ability to survive the harsh conditions of the gastrointestinal tract, including acid and bile exposure, that any orally consumed probiotic must endure. Laboratory and animal studies have documented bacteriocin production, including lactacin B and lactacin F, and their activity against competing pathogens in vitro. The evidence base for L. acidophilus is largely drawn from in vitro and animal research, with earlier reviews characterizing its biochemical and technological properties rather than establishing clinical outcomes in humans. Rigorous human trials confirming specific health benefits remain limited. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 5,851 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 2,072 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+17 more symptoms
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
16417 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
Source →Dietary nano-encapsulated Nigella sativa oil and Lactobacillus acidophilus enhance performance, antioxidant status, and gut health in heat-stressed growing rabbits· Italian Journal of Animal Science · 2026
-
[2]
Source →Clinical and Translational Evaluation of a Lactobacillus Acidophilus Respiratory Mucosal Barrier Platform· Frontiers in Sustainable Development · 2026
-
[3]
PMID 41698905 →Lactobacillus acidophilus KBL409 improves serum indoxyl sulfate via gut microbial changes in a human study· npj Science of Food · 2026
-
[4]
Source →The combination of Lactobacillus acidophilus DSMZ 26280 and Limosilactobacillus reuteri DSMZ 25441 has an impact on clinical course and gut microbiota of children with acute infectious diarrhea· Frontiers in Microbiology · 2026
-
[5]
PMID 42141695 →Probiotic Blend of Lactobacillus acidophilus LA‐5 and Bifidobacterium animalis ssp. Lactis BB‐12 in Non‐Constipated Irritable Bowel Syndrome: A Double‐Blind Randomized Placebo‐Controlled Trial· Journal of Gastroenterology and Hepatology · 2026
-
[6]
PMID 41693686 →Probiotic Supplementation as an Adjuvant Therapy in Pediatric Drug‐Resistant Epilepsy: A Double‐Blind Placebo‐Controlled Trial· Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2026
-
[7]
PMID 42182865 →Toward clinical translation: montmorillonite-enhanced Lactobacillus biofilm alleviates colitis by modulating the gut microbiota–bile acid axis· Materials Today Bio · 2026
-
[8]
PMID 41520710 →Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review· International Journal of Antimicrobial Agents · 2026
-
[9]
Source →Probiotics with ABCG2 expression ability and gut microbiota homeostasis exhibit anti-hyperuricemia potential by promoting uric acid excretion· Journal of Functional Foods · 2025
-
[10]
PMID 40422866 →Probiotic Supplementation Improves Glucose Homeostasis and Modulates Interleukin (IL)-21 and IL-22 Levels in Pediatric Patients with Type 1 Diabetes: A Randomized Placebo-Controlled Trial· Metabolites · 2025